‘Revolution’ Quelled? FDA Warns Firm For ReLuma Stem-Cell Claims

Claims promoting Cell Vitals’ ReLuma skin-care line render the products unapproved drugs, FDA asserts in a Nov. 24 warning letter. Marketed as “A Revolution in Stem Cell Skin Care,” the firm’s products feature cytokines and growth factors harvested from adult stem cells that send “grow and divide” signals to aging skin cells, the company says.

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Archive

More from HBW Insight